How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "6736"
  ["article_id"]=>
  string(4) "6736"
  [1]=>
  string(68) "Merck’s Keytruda gets FDA priority review for high-risk NMIBC"
  ["article_title"]=>
  string(68) "Merck’s Keytruda gets FDA priority review for high-risk NMIBC"
  [2]=>
  string(150) "The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bac"
  ["short_description"]=>
  string(150) "The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bac"
  [3]=>
  string(584) "
The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle 
&#nl
The post Merck’s Keytruda gets FDA priority review for high-risk NMIBC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(584) "
The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle 
&#nl
The post Merck’s Keytruda gets FDA priority review for high-risk NMIBC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/merck-keytruda-high-risk-nmibc/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/merck-keytruda-high-risk-nmibc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the

array(40) {
  [0]=>
  string(4) "6737"
  ["article_id"]=>
  string(4) "6737"
  [1]=>
  string(138) "LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant"
  ["article_title"]=>
  string(138) "LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant"
  [2]=>
  string(150) "The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month precli"
  ["short_description"]=>
  string(150) "The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month precli"
  [3]=>
  string(738) "
The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month preclinical drug discovery project brings together 
&#nl
The post LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(738) "
The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month preclinical drug discovery project brings together 
&#nl
The post LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(186) "https://www.pharmaceutical-business-review.com/news/lunac-therapeutics-led-project-awarded-3-14m-under-innovate-uk-biomedical-catalyst-programme-to-develop-next-generation-anticoagulant/"
  ["blog_url"]=>
  string(186) "https://www.pharmaceutical-business-review.com/news/lunac-therapeutics-led-project-awarded-3-14m-under-innovate-uk-biomedical-catalyst-programme-to-develop-next-generation-anticoagulant/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Pro

The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet 

array(40) {
  [0]=>
  string(4) "6738"
  ["article_id"]=>
  string(4) "6738"
  [1]=>
  string(91) "Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial"
  ["article_title"]=>
  string(91) "Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial"
  [2]=>
  string(150) "SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity"
  ["short_description"]=>
  string(150) "SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity"
  [3]=>
  string(596) "
SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the SENS-111 was 
&#nl
The post Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(596) "
SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the SENS-111 was 
&#nl
The post Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(91) "https://www.pharmaceutical-business-review.com/news/sensorions-seliforant-primary-endpoint/"
  ["blog_url"]=>
  string(91) "https://www.pharmaceutical-business-review.com/news/sensorions-seliforant-primary-endpoint/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b tria

SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory eff

array(40) {
  [0]=>
  string(4) "6739"
  ["article_id"]=>
  string(4) "6739"
  [1]=>
  string(78) "AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC"
  ["article_title"]=>
  string(78) "AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC"
  [2]=>
  string(150) "Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy"
  ["short_description"]=>
  string(150) "Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy"
  [3]=>
  string(600) "
Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy across 54 countries, including the US, the European Union, 
&#nl
The post AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(600) "
Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy across 54 countries, including the US, the European Union, 
&#nl
The post AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(93) "https://www.pharmaceutical-business-review.com/news/astrazeneca-imfinzi-extensive-stage-sclc/"
  ["blog_url"]=>
  string(93) "https://www.pharmaceutical-business-review.com/news/astrazeneca-imfinzi-extensive-stage-sclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC

Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC)

array(40) {
  [0]=>
  string(4) "6740"
  ["article_id"]=>
  string(4) "6740"
  [1]=>
  string(51) "Medincell receives $19m grant for mdc-WWM programme"
  ["article_title"]=>
  string(51) "Medincell receives $19m grant for mdc-WWM programme"
  [2]=>
  string(150) "It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is s"
  ["short_description"]=>
  string(150) "It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is s"
  [3]=>
  string(567) "
It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover 
&#nl
The post Medincell receives $19m grant for mdc-WWM programme appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(567) "
It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover 
&#nl
The post Medincell receives $19m grant for mdc-WWM programme appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(103) "https://www.pharmaceutical-business-review.com/news/medincell-receives-19m-grant-for-mdc-wwm-programme/"
  ["blog_url"]=>
  string(103) "https://www.pharmaceutical-business-review.com/news/medincell-receives-19m-grant-for-mdc-wwm-programme/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Medincell receives $19m grant for mdc-WWM programme

It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contra

array(40) {
  [0]=>
  string(4) "6741"
  ["article_id"]=>
  string(4) "6741"
  [1]=>
  string(99) "WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products"
  ["article_title"]=>
  string(99) "WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products"
  [2]=>
  string(150) "This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus con"
  ["short_description"]=>
  string(150) "This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus con"
  [3]=>
  string(696) "
This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus contract development and manufacturing organization (CDMO) platform, which has 
&#nl
The post WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(696) "
This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus contract development and manufacturing organization (CDMO) platform, which has 
&#nl
The post WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(152) "https://www.pharmaceutical-business-review.com/news/wuxi-atu-and-genemedicine-sign-development-and-manufacturing-agreement-for-oncolytic-virus-products/"
  ["blog_url"]=>
  string(152) "https://www.pharmaceutical-business-review.com/news/wuxi-atu-and-genemedicine-sign-development-and-manufacturing-agreement-for-oncolytic-virus-products/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus

This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project emp

array(40) {
  [0]=>
  string(4) "6742"
  ["article_id"]=>
  string(4) "6742"
  [1]=>
  string(66) "Novartis opens new cell and gene therapies facility in Switzerland"
  ["article_title"]=>
  string(66) "Novartis opens new cell and gene therapies facility in Switzerland"
  [2]=>
  string(150) "The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition"
  ["short_description"]=>
  string(150) "The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition"
  [3]=>
  string(558) "
The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition to the manufacturing of novel CAR-T cell 
&#nl
The post Novartis opens new cell and gene therapies facility in Switzerland appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(558) "
The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition to the manufacturing of novel CAR-T cell 
&#nl
The post Novartis opens new cell and gene therapies facility in Switzerland appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/novartis-cell-gene-therapies/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/novartis-cell-gene-therapies/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Novartis opens new cell and gene therapies facility in Switzerland

The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as 

array(40) {
  [0]=>
  string(4) "6743"
  ["article_id"]=>
  string(4) "6743"
  [1]=>
  string(104) "Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat molluscum contagiosum"
  ["article_title"]=>
  string(104) "Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat molluscum contagiosum"
  [2]=>
  string(154) "“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregiver"
  ["short_description"]=>
  string(154) "“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregiver"
  [3]=>
  string(692) "
“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregivers to choose between a wait-and-see approach or treatments 
&#nl
The post Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat molluscum contagiosum appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(692) "
“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregivers to choose between a wait-and-see approach or treatments 
&#nl
The post Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat molluscum contagiosum appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(157) "https://www.pharmaceutical-business-review.com/news/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-nda-for-vp-102-to-treat-molluscum-contagiosum/"
  ["blog_url"]=>
  string(157) "https://www.pharmaceutical-business-review.com/news/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-nda-for-vp-102-to-treat-molluscum-contagiosum/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat mollusc

“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of

array(40) {
  [0]=>
  string(4) "6744"
  ["article_id"]=>
  string(4) "6744"
  [1]=>
  string(103) "Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention of pregnancy"
  ["article_title"]=>
  string(103) "Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention of pregnancy"
  [2]=>
  string(150) "“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current"
  ["short_description"]=>
  string(150) "“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current"
  [3]=>
  string(678) "
“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current contraceptive options and are eagerly awaiting a 
&#nl
The post Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention of pregnancy appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(678) "
“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current contraceptive options and are eagerly awaiting a 
&#nl
The post Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention of pregnancy appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(156) "https://www.pharmaceutical-business-review.com/news/evofem-biosciences-resubmits-new-drug-application-to-us-fda-for-amphora-for-the-prevention-of-pregnancy/"
  ["blog_url"]=>
  string(156) "https://www.pharmaceutical-business-review.com/news/evofem-biosciences-resubmits-new-drug-application-to-us-fda-for-amphora-for-the-prevention-of-pregnancy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention

“Today’s submission represents a significant step forward for Evofem and for the millions of women who ar

array(40) {
  [0]=>
  string(4) "6745"
  ["article_id"]=>
  string(4) "6745"
  [1]=>
  string(94) "FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma"
  ["article_title"]=>
  string(94) "FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma"
  [2]=>
  string(150) "The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with p"
  ["short_description"]=>
  string(150) "The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with p"
  [3]=>
  string(592) "
The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic 
&#nl
The post FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(592) "
The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic 
&#nl
The post FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/fda-incyte-nda-pemigatinib/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/fda-incyte-nda-pemigatinib/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-12-03 11:05:49"
  ["create_at"]=>
  string(19) "2019-12-03 11:05:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarci

The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pem

array(40) {
  [0]=>
  string(4) "7053"
  ["article_id"]=>
  string(4) "7053"
  [1]=>
  string(116) "FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo plus Yervoy in first-line NSCLC"
  ["article_title"]=>
  string(116) "FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo plus Yervoy in first-line NSCLC"
  [2]=>
  string(159) "The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020. “The FDA’s acceptance"
  ["short_description"]=>
  string(159) "The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020. “The FDA’s acceptance"
  [3]=>
  string(675) "
The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020. “The FDA’s acceptance of our application 
&#nl
The post FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo plus Yervoy in first-line NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(675) "
The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020. “The FDA’s acceptance of our application 
&#nl
The post FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo plus Yervoy in first-line NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(161) "https://www.pharmaceutical-business-review.com/news/fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-plus-yervoy-in-first-line-nsclc/"
  ["blog_url"]=>
  string(161) "https://www.pharmaceutical-business-review.com/news/fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-plus-yervoy-in-first-line-nsclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:46"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo plus

The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15

array(40) {
  [0]=>
  string(4) "7054"
  ["article_id"]=>
  string(4) "7054"
  [1]=>
  string(89) "Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery"
  ["article_title"]=>
  string(89) "Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery"
  [2]=>
  string(150) "Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody "
  ["short_description"]=>
  string(150) "Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody "
  [3]=>
  string(653) "
Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody therapeutics. Specifically, Schrödinger will use its 
&#nl
The post Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(653) "
Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody therapeutics. Specifically, Schrödinger will use its 
&#nl
The post Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/twist-bioscience-announces-strategic-collaboration-with-schrodinger-for-drug-discovery/"
  ["blog_url"]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/twist-bioscience-announces-strategic-collaboration-with-schrodinger-for-drug-discovery/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:46"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery

Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative m